Our research suggests that targeting the extrinsic pathway may offer a mechanistic advantage and implicates a role for combination of STAT5 inhibition with death receptor signaling agonists as a future therapeutic approach in PTCL, although effective TRAIL agonists are still in development [58]. The gene discussed is STAT5A; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.